[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.30. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
December 2015

Cost-effectiveness of Universal BRCA1/2 ScreeningEvidence-Based Decision Making

Author Affiliations
  • 1Anderson School of Management, University of California, Los Angeles
  • 2Division of Cancer Prevention and Control Research and Jonsson Comprehensive Cancer Center, University of California, Los Angeles
  • 3Fielding School of Public Health, University of California, Los Angeles
JAMA Oncol. 2015;1(9):1217-1218. doi:10.1001/jamaoncol.2015.2340

Of the 233 000 breast cancers diagnosed annually in the United States, 5% to 10% are attributable to mutations in the BRCA1 or BRCA2 genes.1 Breast cancers in BRCA mutation carriers are characterized by younger age at onset, bilateral occurrence, and more aggressive subtypes, such as “triple-negative.”1 Female mutation carriers face a 45% to 65% breast cancer risk by age 70 years, and an ovarian cancer risk ranging from 10% to 17% (BRCA2) to 39% (BRCA1). Women found to be BRCA mutation carriers—either through genetic screening or following a cancer diagnosis—may choose to undergo bilateral risk-reducing mastectomy (RRM) and/or salpingo-oophorectomy (RRSO) as an alternative to increased surveillance or chemoprevention. Knowledge of a genetic mutation may have a further impact on fertility decisions, including oocyte retrieval and genetic testing prior to cryopreservation or embryo implantation.

First Page Preview View Large
First page PDF preview
First page PDF preview
×